Genelux Investor Presentation Deck
Highlights of Genelux Execution
GENELUX
I
Olvi-Vec: De-risked late-stage Clinical Program
Ongoing pivotal trial in late-stage Ovarian Cancer and planned Phase 2 trial Adjuvant Maintenance NSCLC
CHOICETM Platform; Broad and Diverse Discovery Engine
Library with over 500 novel vaccinia strains and 110+ transgenes
O
Validating Strategic Partnerships
Newsoara Biopharma (Greater China rights) initiating three Phase 1/2 clinical trials with Olvi-Vec and ELIAS Animal Health (global
rights) initiating canine efficacy studies with V-VET1
Focused Commercial Strategy
US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights
Estimated Billion Dollar Plus Annual Market Opportunity in the U.S.
Potential beyond this in numerous clinical settings
3View entire presentation